Related Experiment Video
Updated: Sep 20, 2026
Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and
Stephen B Hunter1, Daniel J Brat, Jeffrey J Olson
1Department of Pathology and Laboratory Medicine, Emory University Hospital, H-173, NE, Atlanta, GA 30322, USA. stephen_hunter@emory.org
Abstract:
Recent advances in our understanding of the molecular genetic mechanisms underlying diffusely infiltrating brain neoplasms have important implications for the classification and therapy of these tumors. Traditionally, primary brain tumors have been classified histologically; however, it is now clear that tumors within a single histologically defined category are heterogeneous from a molecular genetic perspective. Furthermore, many new experimental therapeutic strategies directed against these almost invariably fatal tumors are aimed at molecular rather than histologic abnormalities. Consequently, the classification of these tumors is in the process of being re-evaluated as underlying molecular genetic mechanisms continue to be elucidated. This review covers traditional histologic based classification of infiltrating glial neoplasms together with molecular abnormalities of these tumors involving p53, epidermal growth factor receptor, the retinoblastoma pathway, platelet derived growth factor receptor, genetic losses on chromosome 10, and loss of heterozygosity on chromosomes 1p and 19q. The contribution of these molecular genetic abnormalities to the classification and therapy of these tumors is discussed. Although at the present no molecular system for the classification of brain tumors has been generally accepted, microarray technologies offer the exciting prospect of practical molecular classification in the future.
Insights
Molecular genetic insights are revolutionizing brain tumor classification and therapy. Understanding these genetic changes, like p53 and EGFR, is key to developing targeted treatments for infiltrating glial neoplasms.
Area of Science:
- Neuro-oncology
- Molecular Genetics
- Cancer Biology
Background:
- Traditional histological classification of brain tumors is insufficient due to molecular heterogeneity.
- Emerging molecular genetic data significantly impacts the understanding and treatment of diffusely infiltrating brain neoplasms.
- Therapeutic strategies are increasingly targeting molecular abnormalities rather than histological types.
Purpose of the Study:
- To review the molecular genetic mechanisms of infiltrating glial neoplasms.
- To discuss the implications of these molecular abnormalities for tumor classification and therapy.
- To explore the potential of future molecular classification systems.
Main Methods:
- Review of current literature on molecular genetics of brain tumors.
- Analysis of specific molecular alterations including p53, epidermal growth factor receptor (EGFR), retinoblastoma pathway, platelet-derived growth factor receptor (PDGFR), chromosome 10 losses, and 1p/19q loss of heterozygosity.
- Discussion of the role of these abnormalities in classification and treatment.
Main Results:
- Diffuse infiltrating brain neoplasms exhibit significant molecular genetic heterogeneity.
- Specific molecular alterations (p53, EGFR, RB pathway, PDGFR, chr10, 1p/19q) are crucial in understanding tumor biology.
- These molecular findings are driving a re-evaluation of traditional classification and therapeutic approaches.
Conclusions:
- Molecular genetic profiling is essential for accurate classification and personalized therapy of brain tumors.
- While no universal molecular classification system exists, microarray technologies hold promise for future practical applications.
- Continued elucidation of molecular mechanisms will further refine treatment strategies for these fatal tumors.
